Literature DB >> 18473344

Investigation of citrullinemia type I variants by in vitro expression studies.

Christoph Berning1, Iris Bieger, Silke Pauli, Tim Vermeulen, Thomas Vogl, Till Rummel, Wolfgang Höhne, Hans Georg Koch, Boris Rolinski, Klaus Gempel, Johannes Häberle.   

Abstract

Mild citrullinemia is an allelic variant of classical citrullinemia type I also caused by deficiency of the urea cycle enzyme argininosuccinate synthetase (ASS). Affected patients comprise a biochemical but no clinical phenotype. However, there is no reliable parameter allowing conclusions regarding the course of the disorder or its type of manifestation. The aim of this study was to test the importance of varying levels of ASS residual activities for the severity at diagnosis. Bacterial in vitro expression studies allowed the enzymatic analysis of purified wild-type and the mutant ASS proteins p.Ala118Thr (c.352G>A), p.Trp179Arg (c.535T>C), p.Val263Met (c.787G>A), p.Arg265Cys (c.793C>T), p.Met302Val (c.904A>G), p.Gly324Ser (c.970G>A), p.Gly362Val (c.1085G>T), and p.Gly390Arg (c.1168G>A). In the chosen system, classical mutations do not show any significant enzymatic activity, whereas mutations associated with a mild course yield significant ASS activity levels. The mutation p.Ala118Thr (c.352G>A) impresses by a high residual activity (62%) but a severe reduction of affinity toward the substrates citrulline and aspartate. This mutation was identified in a hitherto healthy female adult with no history of known citrullinemia who had died during the postpartum period from hyperammonemic coma. The results of this study suggest that even a high level of residual ASS activity is not a reliable prognostic marker for an uneventful clinical course. Determination of ASS residual activities, therefore, cannot help in anticipating the risk of metabolic derangement. This study should guide clinicians as well as patients with mild citrullinemia toward a lifelong awareness of the disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473344     DOI: 10.1002/humu.20784

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  14 in total

1.  Expanded newborn screening: reducing harm, assessing benefit.

Authors:  Bridget Wilcken
Journal:  J Inherit Metab Dis       Date:  2010-05-04       Impact factor: 4.982

2.  Two hypomorphic alleles of mouse Ass1 as a new animal model of citrullinemia type I and other hyperammonemic syndromes.

Authors:  Carlos J Perez; Jean Jaubert; Jean-Louis Guénet; Kirstin F Barnhart; Catherine M Ross-Inta; Vicente C Quintanilla; Isabelle Aubin; Jimi L Brandon; Nancy W Otto; John DiGiovanni; Irma Gimenez-Conti; Cecilia Giulivi; Donna F Kusewitt; Claudio J Conti; Fernando Benavides
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

3.  Favorable long-term outcome following severe neonatal hyperammonemic coma in a patient with argininosuccinate synthetase deficiency.

Authors:  Isabelle De Bie; Emmanuelle Lemyre; Marie Lambert
Journal:  JIMD Rep       Date:  2011-06-22

4.  Identification of mutations underlying 20 inborn errors of metabolism in the United Arab Emirates population.

Authors:  Imen Ben-Rebeh; Jozef L Hertecant; Fatma A Al-Jasmi; Hanan E Aburawi; Said A Al-Yahyaee; Lihadh Al-Gazali; Bassam R Ali
Journal:  Genet Test Mol Biomarkers       Date:  2011-11-22

5.  Hypomorphic citrullinaemia due to mutated ASS1 with episodic ataxia.

Authors:  Arushi Gahlot Saini; Savita Attri; N Sankhyan; Pratibha Singhi
Journal:  BMJ Case Rep       Date:  2018-04-25

6.  Cytosolic Delivery of Argininosuccinate Synthetase Using a Cell-Permeant Miniature Protein.

Authors:  Susan L Knox; Rebecca Wissner; Samantha Piszkiewicz; Alanna Schepartz
Journal:  ACS Cent Sci       Date:  2021-03-18       Impact factor: 14.553

Review 7.  Suggested guidelines for the diagnosis and management of urea cycle disorders.

Authors:  Johannes Häberle; Nathalie Boddaert; Alberto Burlina; Anupam Chakrapani; Marjorie Dixon; Martina Huemer; Daniela Karall; Diego Martinelli; Pablo Sanjurjo Crespo; René Santer; Aude Servais; Vassili Valayannopoulos; Martin Lindner; Vicente Rubio; Carlo Dionisi-Vici
Journal:  Orphanet J Rare Dis       Date:  2012-05-29       Impact factor: 4.123

8.  Citrullinemia with an Atypical Presentation: Paroxysmal Hypoventilation Attacks.

Authors:  Zeynep Öztürk; Tuğba Hirfanoğlu; Aslı İnci; İlyas Okur; Esin Koç; Leyla Tümer; Ebru Arhan; Kürşad Aydın; Ayşe Serdaroğlu
Journal:  J Pediatr Neurosci       Date:  2018 Apr-Jun

9.  Leishmania donovani argininosuccinate synthase is an active enzyme associated with parasite pathogenesis.

Authors:  Ines Lakhal-Naouar; Armando Jardim; Rona Strasser; Shen Luo; Yukiko Kozakai; Hira L Nakhasi; Robert C Duncan
Journal:  PLoS Negl Trop Dis       Date:  2012-10-18

10.  Cross-sectional observational study of 208 patients with non-classical urea cycle disorders.

Authors:  Corinne M Rüegger; Martin Lindner; Diana Ballhausen; Matthias R Baumgartner; Skadi Beblo; Anibh Das; Matthias Gautschi; Esther M Glahn; Sarah C Grünert; Julia Hennermann; Michel Hochuli; Martina Huemer; Daniela Karall; Stefan Kölker; Robin H Lachmann; Amelie Lotz-Havla; Dorothea Möslinger; Jean-Marc Nuoffer; Barbara Plecko; Frank Rutsch; René Santer; Ute Spiekerkoetter; Christian Staufner; Tamar Stricker; Frits A Wijburg; Monique Williams; Peter Burgard; Johannes Häberle
Journal:  J Inherit Metab Dis       Date:  2013-06-19       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.